← Back to directory

Robert W. Wilkinson

Researcher Next ID · RN-036900

Researcher · Immunology and Microbiology

AstraZeneca (United Kingdom)

Cambridge, Singapore

Accepting doctoral researchersFunding unknown
Works count
614
Citation count
13,927
H-index
57
i10-index
215

Research interests

Immunology and Microbiology
Medicine
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Electrolyte and hormonal disorders
Radiopharmaceutical Chemistry and Applications
CAR-T cell therapy research

Publications

  • Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

    Cancer Discovery · 2021 · 10.1158/2159-8290.cd-20-1445

  • Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

    Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-20-0472

  • Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

    Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0724-8

  • CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype

    Cell Reports · 2018 · 10.1016/j.celrep.2018.03.131

  • Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

    Clinical Cancer Research · 2017 · https://doi.org/10.1158/1078-0432.ccr-16-1673

  • Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

    Cancer Immunology Research · 2016 · https://doi.org/10.1158/2326-6066.cir-16-0114

  • Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody

    Cancer Immunology Research · 2015 · https://doi.org/10.1158/2326-6066.cir-14-0191

  • Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

    Cancer Research · 2014 · https://doi.org/10.1158/0008-5472.can-14-1258

  • Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

    Molecular Oncology · 2009 · 10.1016/j.molonc.2009.01.002

  • AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

    Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2979

  • Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase

    Journal of Medicinal Chemistry · 2007 · 10.1021/jm061335f

  • Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation

    American Journal of Physiology-Endocrinology and Metabolism · 1993 · 10.1152/ajpendo.1993.265.2.e230

  • OUTCOME IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS AND HAEMODIALYSIS: 4-YEAR ANALYSIS OF A PROSPECTIVE MULTICENTRE STUDY

    The Lancet · 1987 · 10.1016/s0140-6736(87)91544-3

  • EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION

    Clinical Endocrinology · 1980 · https://doi.org/10.1111/j.1365-2265.1980.tb03135.x

Current projects

    No projects listed.